COVID: treatment trials are still urgent

Nature

  • CORRESPONDENCE

COVID: treatment trials are still urgent

It is obviously difficult to initiate and rapidly enrol people in prospective double-blinded randomized clinical trials of treatments during a rapidly evolving pandemic (see Nature 593, 182–185; 2021) — particularly when extremely effective vaccines are available. But we still need therapeutics. Vaccinations do not give immediate or 100% protection and could be undermined by resistant strains.

The United States is fast losing treatment and control groups as more and more of the population are vaccinated. But not all countries are so fortunate. In India, where the disease is still exploding, treatments could save countless lives.

Worldwide, this is a fundamental scientific and social issue. We must find ways to rapidly set up rigorous prospective clinical trials in places where the vaccine could arrive too late — and to run such trials in health-care systems that are already pushed to the brink.

Nature 594, 26 (2021)

Competing Interests

The author declares no competing interests.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.





Products You May Like

Articles You May Like

G2 Venture Partners raises $500 million to fund sustainable tech
Nelson asks Senate appropriators for more HLS funding
Nintendo teases 2022 release for Breath of the Wild sequel and releases Zelda Game & Watch to tide us over
Amphibious fish get smart — by working out on land
Singapore finance minister says city-state could become a regional hub for green finance

Leave a Reply

Your email address will not be published. Required fields are marked *